Skip to main content
. 2001 Feb 13;98(5):2658–2663. doi: 10.1073/pnas.051624698

Figure 4.

Figure 4

Growth retardation of established LAPC-9 orthotopic tumors and prolongation of survival of tumor-bearing mice by anti-PSCA mAbs. (A) Mice (n = 6) with PSA levels of 2–3 ng/ml (day 9) were treated with either PBS (⧫) or 2 mg 1G8 (■) three times for 1 week followed by nine injections of 1 mg during the next 3 weeks, as indicated by arrows. Tumor growth was monitored by measuring serum PSA levels, and each data point represents the mean PSA level (± SEM). (B) Significant prolongation of survival of 1G8-treated mice (■) in A compared with PBS control mice (⧫). The percentage of survival is shown for each group at the indicated time points. (C) Mice (n = 5) with PSA levels of 64–78 ng/ml (day 13) were given 10 injections of 1 mg of 1G8 for 4 weeks. The percentage of survival is shown for each group at the indicated time points. (D) Mice (n = 6) with PSA levels 14–16 ng/ml (day 7) were injected with 2 mg of 3C5 three times for 1 week, followed by seven injections of 1 mg 3C5 mAb for the next 3 weeks. The percentage of survival is shown for each group at the indicated time points.